Ph-positive ALL treatment using ponatinib plus blinatumomab achieved an estimated 86% two-year event-free survival in the Phase III GIMEMA ALL2820 trial, compared with 67% for imatinib plus chemotherapy. This patient guide explains who the findings apply to, what chemotherapy-free treatment involves, potential risks, relapse monitoring and why event-free survival does not guarantee a permanent cure.